File Download

There are no files associated with this item.

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

박태주

Park, Tae Joo
Morphogenesis Lab.
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

Full metadata record

DC Field Value Language
dc.citation.endPage 1738 -
dc.citation.number 12 -
dc.citation.startPage 1726 -
dc.citation.title ARCHIVES OF PHARMACAL RESEARCH -
dc.citation.volume 39 -
dc.contributor.author Min, Gahee -
dc.contributor.author Ku, Sae-Kwang -
dc.contributor.author Park, Mi Seon -
dc.contributor.author Park, Tae Joo -
dc.contributor.author Lee, Hyun-Shik -
dc.contributor.author Bae, Jong-Sup -
dc.date.accessioned 2023-12-21T23:06:39Z -
dc.date.available 2023-12-21T23:06:39Z -
dc.date.created 2016-11-04 -
dc.date.issued 2016-12 -
dc.description.abstract A certain nucleosomal protein-high mobility group box-1 (HMGB1)-has recently been established as a late mediator of sepsis, with a relatively wide therapeutic window for pharmacological intervention. Pelargonidin (PEL) is a well-known red pigment found in plants; it has important biological activities that are potentially beneficial for human health. In the present study, we investigated whether PEL can modulate HMGB1-mediated inflammatory responses in human umbilical vein endothelial cells (HUVECs) and in mice. The anti-inflammatory activities of PEL were determined by measuring permeability, leukocyte adhesion and migration, and activation of pro-inflammatory proteins in HMGB1-activated HUVECs and mice, as well as the beneficial effects of PEL on survival rate in the mouse sepsis model. The data showed that PEL had effectively inhibited lipopolysaccharide (LPS)-induced release of HMGB1 and suppressed HMGB1-mediated septic responses, such as hyperpermeability, adhesion and migration of leukocytes, and expression of cell adhesion molecules. Furthermore, PEL inhibited the HMGB1-mediated production of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6), as well as the activation of nuclear factor-kappa B (NF-kappa B) and extracellular signal-regulated kinases 1 and 2 (ERK1/2). Collectively, these results indicate that PEL could be used to treat various severe vascular inflammatory diseases via the inhibition of the HMGB1 signaling pathway. -
dc.identifier.bibliographicCitation ARCHIVES OF PHARMACAL RESEARCH, v.39, no.12, pp.1726 - 1738 -
dc.identifier.doi 10.1007/s12272-016-0834-5 -
dc.identifier.issn 0253-6269 -
dc.identifier.scopusid 2-s2.0-84992183782 -
dc.identifier.uri https://scholarworks.unist.ac.kr/handle/201301/21057 -
dc.identifier.url http://link.springer.com/article/10.1007%2Fs12272-016-0834-5 -
dc.identifier.wosid 000391395300013 -
dc.language 영어 -
dc.publisher PHARMACEUTICAL SOC KOREA -
dc.title Anti-septic effects of pelargonidin on HMGB1-induced responses in vitro and in vivo -
dc.type Article -
dc.description.isOpenAccess FALSE -
dc.relation.journalWebOfScienceCategory Chemistry, Medicinal; Pharmacology & Pharmacy -
dc.identifier.kciid ART002173835 -
dc.relation.journalResearchArea Pharmacology & Pharmacy -
dc.description.journalRegisteredClass scie -
dc.description.journalRegisteredClass scopus -
dc.description.journalRegisteredClass kci -
dc.subject.keywordAuthor Pelargonidin -
dc.subject.keywordAuthor HMGB1 -
dc.subject.keywordAuthor Sepsis -
dc.subject.keywordAuthor Inflammation -
dc.subject.keywordAuthor HUVEC -
dc.subject.keywordPlus EXTRACELLULAR-MATRIX PROTEINS -
dc.subject.keywordPlus ENDOTHELIAL-CELL MONOLAYERS -
dc.subject.keywordPlus SMOOTH-MUSCLE-CELLS -
dc.subject.keywordPlus PROINFLAMMATORY CYTOKINE -
dc.subject.keywordPlus INFLAMMATORY RESPONSES -
dc.subject.keywordPlus ORGAN DYSFUNCTION -
dc.subject.keywordPlus ANIMAL-MODELS -
dc.subject.keywordPlus SEVERE SEPSIS -
dc.subject.keywordPlus THERAPEUTIC TARGET -
dc.subject.keywordPlus LATE MEDIATOR -

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.